← Research library

The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.

Animal research · 1997

What was studied
Rat metabolism and enzyme preparations
Main finding
Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.

Study data at a glance

Participants or experimental model
Rat metabolism and enzyme preparations
Reported results
Rat-brain CPG increased approximately 2.5-fold one hour after GVS-111 administration. Enzyme experiments supported conversion to CPG; these findings do not prove that CPG accounts for every Noopept effect.
Study limitations and source details

Study limitations

  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Source details

Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.

Abstract reviewed

Sources checked

Citation

Animal / experimentalEnglish abstract

Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SB. The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. European journal of drug metabolism and pharmacokinetics

Study source ↗ · DOI 10.1007/bf03189814 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards